Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology

Cao, Hongwen; Wang, Dan; Gao, Renjie; Li, Chenggong; Feng, Yigeng; Chen, Lei

doi:10.7717/peerj.13481

Cited by 2 publications

(3 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…QLD is widely used for CRPC therapy in many clinical settings in China 16 , 15 . The combination of QLD with docetaxel improves the therapeutic effectiveness of docetaxel against CRPC by enhancing cancer cells' sensitivities to docetaxel cytotoxicity 14 .…”

Section: Discussionmentioning

confidence: 99%

“…In 2021, our group reported that QLD suppressed docetaxel resistance and aerobic glycolysis in patients with CRPC, at least in part, by the regulation of long non-coding RNA SNHG10 14 . In 2022, their bio-informatic study further suggested a total of 51 active components and 149 potential bio-targets for QLD in the treatment of CRPC 15 . However, it is still unclear if QLD can also improve the sensitivity of the antiandrogen drug against prostate cancer cells and their underlying mechanisms.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo

Cao¹,

Wu²,

Gao³

et al. 2023

J. Cancer

Self Cite

View full text Add to dashboard Cite

QiLing Decoction (QLD) showed therapeutic effects against prostate cancer with an unclear underlying mechanism. This study explored the underlying mechanisms of QLD against castration-resistant prostate cancer (CRPC). Clinical specimens were collected from the patients with CRPC. Stable cells including knockdown and overexpression cell lines were established by plasmid transfection. The xenograft animal model was constructed. Cell viability was determined by using cell-counting kit 8 assay. Biochemical assays were used to determine the levels of iron (Fe 2+ ) and lipid reactive oxygen species (ROS). qRT-PCR and Western blotting were used to determine levels of target genes, respectively. Treatment of QLD inhibited ferroptosis suppressor protein (FSP) 1 at mRNA and protein levels in patients with CRPC. Additionally, cells treated with QLD-containing serum displayed a decrease in cell viability and an increase in Fe 2+ and lipid ROS with or without erastin, whereas ferroptosis inhibitor reversed QLD-induced ferroptosis. The regulatory effects of QLD on PC3 cell ferroptosis were associated with its inhibitory effects against FSP1. Consistently, QLD inhibited PC3 tumor growth by inhibiting FSP1. Moreover, treatment of QLD increased the sensitivity of PC3-AbiR cells to abiraterone by inhibiting FSP1. QLD promoted ferroptosis in CRPC cells in part by inhibiting FSP1 in vitro and in vivo.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo

Cao¹,

Wu²,

Gao³

et al. 2023

J. Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…In silico studies Prostate cancer related gene identi cation Target genes related to prostate cancer were identi ed by exploring the term prostate cancer in the GeneCards (https://www.genecards.org/) and DisGeNET (https://www.disgenet.org/) databases and different targets were downloaded into Excel format (Cao et al, 2022). The targets from two databases pooled and duplicates were removed to obtain the nal targets for the prostate cancer.…”

Section: Reagents and Chemicalsmentioning

confidence: 99%

Quercetin loaded and alginate sealed β-Glucan particles-based drug delivery system against DU145 a prostate cancer cell line: Integrating network pharmacology, molecular docking and in vitro studies

TRIVEDI,

Upadhyay,

Prabhakar

2024

Preprint

View full text Add to dashboard Cite

Background Prostate cancer remains a challenge in healthcare, being the second most common male cancer demanding innovative therapeutic approaches and treatment techniques. This study integrates in silico and in vitro methods for the investigation of the potential anticancer effects of quercetin-loaded and alginate-sealed β-Glucan particles derived from mushroom Agaricus bisporus and yeast against the DU145 cell line. Methods Prostate cancer-related genes were identified from DisGeNET and GeneCards databases, followed by target prioritization using Swiss Target Prediction software. Venny 2.1 was used for the determination of common targets between β-Glucan, Quercetin, and prostate cancer and PPI network was constructed using STRING database. CB dock online server was used for molecular docking and DU145, RAW264.7 cell lines were used for the determination of cytotoxicity against prostate cancer and healthy cells. Results Molecular docking revealed that quercetin has superior binding affinity compared to β-Glucan with selected prostate cancer-related targets. In vitro evaluation using MTT assays demonstrated the cytotoxic effects of quercetin-loaded and alginate-sealed particles against DU145 prostate cancer cells. Apoptosis induction, ROS generation, and lysosomal pH alterations underscore the potential of quercetin-loaded and alginate-sealed β-Glucan particles as promising therapeutic agents for prostate cancer. Conclusions Our study showed systematic analyses of the effect of hollow β-Glucan particles, Quercetin, and Quercetin alginate sealed particles against DU145 cells and found that formulation exhibits superior anticancer activity against prostate cancer cell line. Quercetin-loaded alginate-sealed particles showed very little cytotoxicity against healthy cell line RAW264.7. Future studies focusing on preclinical validation, pharmacokinetic profiling, and clinical trials to assess translational potential and optimize therapeutic strategies can help get impactful findings.

show abstract

Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology

Cited by 2 publications

References 41 publications

QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo

QiLing Decoction promotes ferroptosis of castration-resistant prostate cancer cells by inhibiting FSP1 in vitro and in vivo

Quercetin loaded and alginate sealed β-Glucan particles-based drug delivery system against DU145 a prostate cancer cell line: Integrating network pharmacology, molecular docking and in vitro studies

Contact Info

Product

Resources

About